# Notice of Intent - Nucleic acid–based reagents for in vivo transient protein expression

Canonical: https://abierto.us/opportunities/nih26006363intentnotice

- Solicitation number: NIH-26-006363-IntentNotice
- Notice type: Presolicitation
- Status: Closed. Deadline was February 14, 2026 at 1:00 PM EST
- Department: Department of Health and Human Services
- Agency: Office of the Assistant Secretary for Administration (Asa)
- Contracting office: Program Support Center Acq MGMT SVC (75P001)
- NAICS: 325413 In-Vitro Diagnostic Substance Manufacturing
- Product or service code: 6550 In Vitro Diagnostic Substances, Reagents, Test Kits and Sets
- Place of performance: Philadelphia, Pennsylvania
- County: Philadelphia County (FIPS 42101). https://abierto.us/counties/philadelphia-county-pa-42101
- City: Philadelphia. https://abierto.us/cities/philadelphia-pa-4260000
- First posted: January 30, 2026
- Last posted: January 30, 2026
- SAM.gov: https://sam.gov/workspace/contract/opp/e3675be32c5f47f3801816ac68017a33/view

## Description

This notice is not a request for competitivequotations or capability statements. The intent of this notice is for informational purposes only. Please do not call or submit questions/inquiries via email, concerning this presolicitation notice update.

The intent is to award a contract on a solesource basis instead of competititon for Nucleic acid–based reagents for in vivo transient protein expression forthe National Cancer Institute and Center for Cancer Research. The supplies required are nucleic acid-based reagents. The proposed work focuses on the use of nucleic acid-based reagents to investigate preventive strategies against viral infection of HIV/Simian Immunodeficiency virus (SIV) and HTLV in preclinical models.

The proposed studies will utilize nucleic-acid based reagents that express viral antigens as a preventive treatment to be tested in appropriate models. Nucleic acid-based reagents have been used in prior preclinical studies, conducted by the AMRVS, as preventive countermeasures against viral infections, demonstrating the ability to induce protective immune responses in relevant experimental models.

Previous work has shown that such reagents can be designed to express viral antigens that are safe and confer protection against the target pathogen. Collectively, these findings support further preclinical studies as preventive strategies. The requested reagents will provide broader activity against related viral subtypes and other cancer-inducing viruses. It is important to use the same supplier for these reagents in order to ensure consistency with materials used in previous preclinical studies.

These reagents can vary in formulation, synthesis methods and purity, and such differences may introduce variability that complicates interpretation of experimental results. Using reagents from the same suppliers enables direct comparison with previously generated data, support reproducibility and ensure continuity in experimental design and data analysis.

## Publications

- January 30, 2026: Presolicitation, due February 14, 2026 at 1:00 PM EST. Notice 16f0d3a0ac4244809319904e2656f3c7. https://sam.gov/workspace/contract/opp/16f0d3a0ac4244809319904e2656f3c7/view
- January 30, 2026: Presolicitation, due February 14, 2026 at 1:00 PM EST. Notice e3675be32c5f47f3801816ac68017a33. https://sam.gov/workspace/contract/opp/e3675be32c5f47f3801816ac68017a33/view

## Points of contact

- Ivan Mora-Juarez, ivan.mora-juarez@hhs.gov, 3014430055

---
Source: SAM.gov Contract Opportunities bulk extract. Confirm deadlines on SAM.gov before responding. Cite https://abierto.us/opportunities/nih26006363intentnotice.